News
9 April 2021
Óskare Capital’s First Portfolio Company, Octarine Bio, Raises $3 Million USD
April 2021
28 January 2021
Guest Post: The Symbiosis of Regulation and Science – Óskare Capital SAS
ÓSKARE Fund I & Medical Cannabinoids
20 January 2021
ÓSKARE CAPITAL STRENGTHENS TEAM AND EXTENDS COVERAGE TO THE AMERICAS BY WELCOMING JD WECHSLER AS VENTURE PARTNER
As we prepare for our first closing in Q1 2021, Óskare Capital is pleased to announce that JD…
7 October 2020
ÓSKARE CAPITAL STRENGTHENS TEAM WITH TWO NEW MEMBERS
Óskare Capital is pleased to announce that Oliver Lamb will be joining as Co-Founder and Investment Manager in…
9 July 2020
Broughton bids farewell to Mercia
Mercia Asset Management has lost its investment director and university lead Nicola Broughton to a new $171m fund…
9 July 2020
Central Bank signs off on €150m legal cannabis fund
THE Central Bank of Ireland has given the green light for an Irish domiciled investment fund that is…
9 July 2020
Medical cannabis private equity fund established
Ireland's first ever private equity medical cannabis fund has been established. The new venture has been set up…
9 July 2020
Cannabis thérapeutique : un fonds veut doper l’écosystème européen
Oskare Capital lance Oskare Fund I, un fonds d'investissement qui va cibler des sociétés européennes développant des thérapies…
31 May 2020
Octarine receives funding to develop biosynthetic platform for cannabinoid and psilocybin derivatives
Octarine Bio IVS (“Octarine” or the “Company”), a synthetic biology company developing functionally superior cannabinoid and psilocybin derivatives…